Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics by King, Glenn F.

Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics (Hardcover) (ISBN-13: 9781849736633)

Vendor: Glenn F. King
Product type: Books
Format: Hardcover
$237.00
$237.00
$237.00
Subtotal: $237.00
Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics by King, Glenn F.

Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics

$237.00
Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics by King, Glenn F.

Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics

$237.00
Format: Hardcover
Description
Description
x
The pharmaceutical industry has become increasingly interested in biologics from animal venoms as a potential source for therapeutic agents in recent years, with a particularly emphasis on peptides. To date six drugs derived from venom peptides or proteins have been approved by the FDA, with nine further agents currently being investigated in clinical trials.This unique book provides an up to date and comprehensive account of the potential of peptides and proteins from animal venoms as possible therapeutics.The first text to focus on this fascinating area and bridging an important gap, it provides the reader with essential and current knowledge on this fast-developing area. Venoms to Drugs will find wide readership with researchers working in academia and industry working in all medicinal and pharmaceutical areas.

Author: Glenn F. King
ISBN-10: 1849736634
ISBN-13: 9781849736633
Publisher: Royal Society of Chemistry
Language: English
Published: 02/10/2015
Pages: 320
Format: Hardcover
Weight: 1.40lbs
Size: 9.20h x 6.30w x 0.90d
By Glenn F. King
By Glenn F. King
x

Professor Glenn King has been working on animal venoms since 1996.He has extensive experience in the discovery, production, and structural and functional characterization of venom proteins, and is intimately aware of the issues surrounding their development as drugs and insecticides. In 2006, Professor King founded an agricultural biotechnology company, Vestaron Corporation, that is developing spider-venom peptides discovered in the lab as bioinsecticides.His current research is largely focussed on the development of venom peptides as analgesics for the treatment of chronic pain.

Recently Viewed Products